Re: Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Final Analysis from a Multicentre, Open-label, Prospective Phase 2 Trial [0.03%]
联合阿特朱单抗和放疗的膀胱保留疗法（BPT-ART）治疗侵袭性膀胱癌：一项多中心、开放标签、前瞻性II期临床试验的最终分析
Jumei Zhou,Ping Liu
Jumei Zhou
KIM-1 in Advanced Papillary and Clear Cell Renal Cell Carcinoma [0.03%]
Kim-1在乳头状和透明细胞肾细胞 carcinoma中的表达
Sara Coca Membribes,Wenxin Xu,Cristina Suárez et al.
Sara Coca Membribes et al.
Kidney injury molecule 1 (KIM-1) is a promising biomarker in adjuvant clear cell renal cell carcinoma (ccRCC), but its relevance in advanced ccRCC or papillary RCC (pRCC) remains unclear. CALYPSO (NCT02819596) was a prospective, multi-arm t...
Re: App-based Therapy for Female Patients with Urinary Incontinence in Germany (DINKS): A Single-blind, Randomized Controlled Trial [0.03%]
德国基于应用程序的女性尿失禁患者行为疗法疗效研究（DINKS试验）：单盲随机对照试验
Sherbano Ali Khan,Mrunal Hiwase,Michael O&#x;Callaghan
Sherbano Ali Khan
Re: HIF-2-dependent Regulation of PTHrP and Paraneoplastic Hypercalcemia in Aggressive Clear Cell Renal Cell Carcinoma [0.03%]
致死性透明细胞肾细胞癌中HIF-2依赖的PTHrP调节及恶病质相关高钙血症的作用机制研究
Hangbiao Zhang,Yifan Liu,Yuanbo Zong et al.
Hangbiao Zhang et al.
Reply to Therese Kang and Wee Loon Ong's Letter to the Editor re: Ragu Ratnakumaran, Douglas H. Brand, Archana Sasitharan, et al. Exploring Factors Associated with Late Urinary Toxicity After Prostate Stereotactic Body Radiotherapy: Findings from the PACE-B Study. Eur Urol 2026;89:71-9 [0.03%]
关于Therese Kang和Wee Loon Ong来信回应有关前列腺体 stereotactic body radiotherapy 后晚期尿毒症的影响因素探讨的研究来信回复Eur Urol 2026;89:71-9
Ragu Ratnakumaran,Alison C Tree
Ragu Ratnakumaran
Re: Female Reproductive Tract-on-a-Chip for Selecting Sperm with Ultra-low DNA Fragmentation Index [0.03%]
用于选择DNA片段化指数极低精子的女性生殖道芯片回复
Paula A Velilla,Walter D Cardona Maya
Paula A Velilla
Re: Three versus Six Cycles of Platinum-Based Chemotherapy Followed by Avelumab Maintenance as First-Line Treatment for Advanced Urothelial Cancer: The Phase II DISCUS Trial [0.03%]
关于六线与三线铂基化疗后维持使用阿维鲁单抗作为晚期尿路上皮癌一线治疗的比较：II期DISCUS试验
Duygu Ercan Uzundal,Fahriye Tuğba Köş
Duygu Ercan Uzundal
Rodolfo Montironi,Gianluca Giannarini,Alessia Cimadamore et al.
Rodolfo Montironi et al.
Prospective Comparison of 64Copper [64Cu]SAR-bisPSMA vs 68Gallium[68Ga] PSMA-11 PET/CT for Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy (Co-PSMA Trial) [0.03%]
前列腺根治术后生化复发的64铜[SUP]64 Cu[/SUP]SAR-bisPSMA与68镓[ SUP ]68Ga PSMA-11 PET/CT前瞻性对比研究(Co-PSMA试验)
Sobia Khan,Nathan Papa,Andrew Kneebone et al.
Sobia Khan et al.
Background and objective: Prostate-specific membrane-antigen positron emission tomography (PSMA-PET) has transformed management of prostate cancer biochemical recurrence (BCR) with higher diagnostic accuracy than previous...